COVID-19 area

Since the onset of the SARS-CoV-2 epidemic, CPO Piedmont has been engaged in the collection and analysis of data relating to the new Coronavirus through the following studies.

    Evaluate whether the infusion of plasma containing anti-SARS-CoV-2 neutralizing antibodies obtained from subjects recovering from COVID-19, or of plasma from donors not in contact with SARS-CoV-2, in triple administration every 48 hours, in addition to standard treatment, is more effective than standard treatment alone on the outcome of COVID-19 patients with recent development or recent worsening (max 5 days) of acute respiratory failure requiring ventilatory support.
  • Monitoring, for descriptive and analytical purposes, of cases with access to the AOU City of Health and Science of Turin with a diagnosis of COVID-19
    Monitors COVID-19 cases with access to the AOU for descriptive purposes (the frequency of new diagnoses, access to the emergency room, admissions and referrals to home or other facilities, clinical and epidemiological characteristics at the entrance, intra-hospital path , treatment modalities, incidence of complications, outcome) and analytical (with estimation of the prognostic significance of the personal and clinical characteristics, of the individual conditions and risk factors, of previous and in-hospital therapies on the evolution of clinical severity, on need and type of ventilatory support, duration of hospitalization, recovery, mortality, re-admission to hospital and survival 6 months from diagnosis).
  • Study on the impact of COVID-19 in the primary care setting in Piedmont
    Evaluate the response of the territory, in particular the contribution of General Practitioners (GPs), in the management of COVID-19 patients. Investigate which symptoms best predict the outcome of the swab in order to optimize available resources and make the GP's role more efficient in identifying new cases.
  • Epidemiological studies on SARS-CoV-2
    Evaluates characteristics associated with clinical severity and mortality in cohorts of COVID-19 patients.

In some studies and projects of the CPO already underway and relating to other issues, specific investigative initiatives dedicated to COVID-19 have been launched. For example, in the context of the NINFEA and Piccolipiù cohort studies, new questionnaires on COVID-19 were administered to the participants in order to investigate both aspects of a purely clinical nature and the socioeconomic effects that the pandemic had in the family.